Isolation and characterization of CD34+ blast-derived exosomes in acute myeloid leukemia

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Hong, Chang Sook ^a   Muller, Laurent ^a,b   Boyiadzis, Michael ^a,c   Whiteside, Theresa L ^a,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIBODY; NANOBEAD; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR NKG2D; CD34 ANTIGEN; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY AFFINITY; ARTICLE; CD34 SELECTION; CELL ISOLATION; CONTROLLED STUDY; DOWN REGULATION; EXOSOME; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; NATURAL KILLER CELL; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; ACUTE MYELOBLASTIC LEUKEMIA; BLOOD; CELL FRACTIONATION; CHEMISTRY; LEUKOCYTE; MEMBRANE MICROPARTICLE; METABOLISM; PATHOLOGY; PROCEDURES; THROMBOCYTE; TUMOR CELL CULTURE; ULTRACENTRIFUGATION;

ANTIGENS, CD34; BIOMARKERS, TUMOR; BLOOD PLATELETS; CELL FRACTIONATION; CELL-DERIVED MICROPARTICLES; EXOSOMES; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES; TUMOR CELLS, CULTURED; ULTRACENTRIFUGATION;

EID: 84905487789     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103310     Document Type: Article

References (27)

1. Burnett A, Wetzler M, Lowenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Onc 29(5): 487-94.
2. Horton SJ, Huntly BJ (2012) Recent advances in acute myeloid leukemia stem cell biology. Haematologica 97: 966-74.
3. EL Andaloussi S, Mäger I, Breakefield XO, Wood MJ (2013) Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 12: 347-57.
4. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, et al. (2012) Melanoma exosomes educate bone marrow progenitor cells toward a prometastatic phenotype through MET. Nat Med 18: 883-91.
5. Filipazzi P, Burdek M, Villa A, Rivoltini L, Huber V (2012) Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol 22: 342-9.
6. Whiteside TL (2013) Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Transact 41: 245-51.
7. Thery C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2: 569-79 (Pubitemid 37328732)
8. Zhang HG, Zhuang X, Sun D, Liu Y, Xiang X, et al. (2012) Exosomes and immune surveillance of neoplastic lesions: a review. Biotech Histochem 87: 161-8.
9. Taylor DD, Gercel-Taylor C (2011) Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol 33: 441-54.
10. Martínez-Lorenzo MJ, Anel A, Alava MA, Piñeiro A, Naval J, et al. (2004) The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res 295: 315-29. (Pubitemid 38490488)
11. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, et al. (2002) Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 195: 1303-16. (Pubitemid 34564332)
12. Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, et al. (2006) Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 66: 9290-8. (Pubitemid 44521151)
13. Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M (2011) Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica 96: 1302-9.
14. Hong CS, Muller L, Whiteside TL, Boyiadzis M (2014) Plasma Exosomes as Markers of Therapeutic Response in Patients with Acute Myeloid Leukemia. Front Immunol 5: 160
15. Muller L, Hong C-S, Stolz DR, Watkins S, Whiteside TL (2014) Isolation of biologically active exosomes from human plasma. Ms. submitted.
16. Aatonen M, Grönholm M, Siljander PR (2012) Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost 38: 102-13.
17. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, et al. (1991) Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation, Blood 77: 2031-2036.
18. Larizza L, Magnani I, Beghini A (2005) The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 46: 247-55. (Pubitemid 40185956)
19. Teague RM, Kline J (2013) Immune evasion in acute myeloid leukemia: current concepts and future directions. J Immunother Cancer 1(13).
20. Whiteside TL (2014) Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 63: 67-72.
21. Logozzi M1, De Milito A, Lugini L, Borghi M, Calabrò L, et al. (2009) High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 4(4):e5219.
22. Mathivanan S, Lim JW, Tauro BJ, Ji H, Moritz RL, et al. (2010) Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol Cell Proteomics 9: 197-208.
23. Tauro BJ, Greening DW, Mathias RA, Mathivanan S, Ji H, et al. (2013) Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids. Mol Cell Proteomics 12: 587-98.
24. van Stijn A, van der Pol MA, Kok A, Bontje PM, et al. (2003) Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica 88: 497-508. (Pubitemid 36648439)
25. Ishikawa F1, Yoshida S, Saito Y, Hijikata A, Kitamura H, et al. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25: 1315-21.
26. Oyan AM, Bø TH, Jonassen I, Ulvestad E, Gjertsen BT, et al. (2005) CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry B Clin Cytom 64: 18-27. (Pubitemid 40960408)
27. Blair A, Hogge DE, Sutherland HJ (1998) Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+/CD71-/HLA-DR+. Blood 92: 4325-4335. (Pubitemid 28544350)